Novo Nordisk A/S : Files For EU Approval of Obesity Drug

By Dominic Chopping

Danish pharmaceutical company Novo Nordisk AS said Friday that it has filed for European Union regulatory approval of its semaglutide weight-loss drug.

The company has submitted a Marketing Authorisation Application to the European Medicines Agency for semaglutide as a treatment for obese or overweight adults in conjunction with a reduced-calorie diet and increased physical activity.

Novo Nordisk earlier this month submitted a new drug application to the U.S. Food and Drug Administration for the drug.

"It is a milestone for Novo Nordisk but more importantly it represents a new treatment option with the potential to transform the medical management for people living with obesity in Europe," Novo Nordisk Chief Scientific Officer Mads Krogsgaard Thomsen said.

Semaglutide is a glucagon-like peptide-1 drug, or GLP-1, that helps enhance the production of insulin and regulate appetite.

Write to Dominic Chopping at [e-mail]

(END) Dow Jones Newswires

12-18-20 0451ET